RYBREVANT®? (amivantamab) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer

Posted: September 15, 2024 at 2:45 am

Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease1

See the rest here:
RYBREVANT®? (amivantamab) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer

Related Posts